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Abstract
Rationale Disturbed reward processing in humans has been
associated with a number of disorders, such as depression,
addiction, and attention-deficit hyperactivity disorder. The
endocannabinoid (eCB) system has been implicated in
reward processing in animals, but in humans, the relation
between eCB functioning and reward is less clear.
Objectives The current study uses functional magnetic
resonance imaging (fMRI) to investigate the role of the
eCB system in reward processing in humans by examining
the effect of the eCB agonist Δ
9-tetrahydrocannabinol
(THC) on reward-related brain activity.
Methods Eleven healthy males participated in a randomized
placebo-controlled pharmacological fMRI study with ad-
ministration of THC to challenge the eCB system. We
compared anticipatory and feedback-related brain activity
after placebo and THC, using a monetary incentive delay
task. In this task, subjects are notified before each trial
whether a correct response is rewarded (“reward trial”)o r
not (“neutral trial”).
Results Subjects showed faster reaction times during
reward trials compared to neutral trials, and this effect
was not altered by THC. THC induced a widespread
attenuation of the brain response to feedback in reward
trials but not in neutral trials. Anticipatory brain activity
was not affected.
Conclusions These results suggest a role for the eCB
system in the appreciation of rewards. The involvement of
the eCB system in feedback processing may be relevant for
disorders in which appreciation of natural rewards may be
affected such as addiction.
Keywords Reward.THC.Endocannabinoid system.
fMRI.Monetary reward.Addiction
Introduction
Disturbed reward processing is associated with a number of
psychiatric disorders in humans, such as depression
(Domschke et al. 2008), addiction (Pacher et al. 2006),
and attention-deficit hyperactivity disorder (Strohle et al.
2008). Animal studies have indicated that the endocanna-
binoid (eCB) system in the brain plays an important role in
reward processing (Solinas et al. 2007). This system
consists of eCB receptors and eCB ligands that work on
these receptors and has a retrograde synaptic effect on the
release of various neurotransmitters, such as GABA,
glutamate, and dopamine (Pertwee 2008). High densities
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DOI 10.1007/s00213-011-2428-8of eCB receptors are found in brain structures associated
with reward processing, including the ventral tegmental
area, the nucleus accumbens, and prefrontal cortex (Ameri
1999; Gardner 2005). Endocannabinoid agonists have
rewarding effects, as has been shown in animals (Gardner
2005; Solinas et al. 2007). Also, blocking the eCB system
with the antagonist rimonabant has been shown to reduce
the rewarding effects of drugs of abuse such as opiates,
nicotine, alcohol, and cocaine, indicating that the eCB
system is involved in the neurobiological mechanism
underlying drug addiction (De Vries and Schoffelmeer
2005; Maldonado et al. 2006). Further, the cannabinoid
agonist Δ
9-tetrahydrocannabinol (THC) has rewarding
properties by increasing dopamine transmission in the
nucleus accumbens (Gardner 2005). However, whether
these findings can be extrapolated to humans is unclear.
The location of eCB receptors in the human brain
suggests that the eCB system is also involved in human
reward processing (Glass et al. 1997; Terry et al. 2009). An
extensive network of brain regions is involved, including
limbic structures (notably striatum) and frontal regions
(Bjork and Hommer 2007; Knutson et al. 2001a; Knutson
and Cooper 2005; O'Doherty 2004). Chronic cannabis use
has been shown to blunten the response of the striatum in
anticipation of a reward (Van Hell et al. 2010). Similarly,
treatment with the eCB antagonist rimonabant in healthy
volunteers resulted in reduced striatal brain activity during
reward processing (Horder et al. 2010). Chronic use of
rimonabant has been demonstrated to reduce overweight
and smoking and to cause depression, but the potential
involvement of the reward system is unclear (Cahill and
Ussher 2007). However, use of rimonabant in healthy
subjects is thwarted by the withdrawal of this drug from
registration, following an increased risk of depression and
suicide in obese patients (Le Foll et al. 2009). This
essentially precludes further use of this drug for elucidating
the role of eCB in human brain function. An alternative
approach, where the eCB system is challenged with THC,
canalsoprovidea powerful toolforstudyingits roleinreward
processing in humans. THC is the main psychoactive
constituent of cannabis and possesses rewarding as well as
addictive properties (Pertwee 2008). Human studies have
shown both increased dopamine transmission as measured
with positron emission tomography (PET; Bossong et al.
2009) and no change in striatal dopamine transmission after
THC administration, measured with PET (Stokes et al. 2009)
or single photon emission tomography (Barkus et al. 2011).
Here, a pharmacological functional magnetic resonance
imaging (fMRI) study is presented that examines the
involvement of the eCB system in anticipation to a reward
as well as reception of the reward. A monetary incentive
delay (MID) task is applied (Knutson et al. 2001b), an
established reward paradigm which provides a measure of
sensitivity to anticipation of reward as well as sensitivity to
notification that the reward has been won (Hommer et al.
2011). Previous studies using this paradigm have indicated
that anticipation of a reward activates the ventral striatum,
and especially the nucleus accumbens, while the reward
itself activates frontal brain areas (Knutson et al. 2001a;
Knutson et al. 2001b). It was expected that THC would
increase baseline dopamine transmission in the reward
system. As a result, it was expected that the fMRI response
to a natural reward would be decreased, especially in
regions in which eCB receptors are densely distributed,
such as the nucleus accumbens and prefrontal cortex.
Methods
This study is part of the Pharmacological Imaging of the
Cannabinoid System (PhICS) project, a comprehensive
research project on the role of the endocannabinoid system
in the regulation of cognitive brain function in healthy
volunteers and patients with psychiatric disorders. Methods
of the entire study are reported in detail in a methodological
paper (Van Hell et al. 2011). The study is registered in both
the EudraCT database (2007-004247-30) and the Dutch
Trial Register (NTR1787).
Subjects
Fourteen healthy male subjects participated in a randomized
placebo-controlled cross-over pharmacological MRI study
with THC administration. For ethical reasons, subjects
needed to be occasional cannabis users (at least four times a
year and at most once a week) who never had negative
experiences after cannabis use. Subjects were in good
health as assessed by medical history, physical examination,
electrocardiogram, and routine laboratory tests. In- and
exclusion criteria are described in further detail in Van Hell
et al. (2011). All volunteers gave written informed consent
before entry into the study and were compensated for their
participation. The study was approved by the Ethical
Committee of the University Medical Centre Utrecht in
accordance with the Declaration of Helsinki 2008.
Results are reported on eleven out of the fourteen
included subjects. Two data sets were incomplete, due to
respectively a technical malfunction of the scanner and
feelings of anxiety during the second scanning session. One
subject was excluded from analysis due to movement
artefacts. Subject characteristics are summarized in Table 1.
Procedure
At a training session, subjects practiced the procedure of
drug administration (inhalation), and participants were
982 Psychopharmacology (2012) 219:981–990familiarized with the scan protocol in a mock scanner to
reduce stress effects on the following test days. The actual
study consisted of two test days, separated by at least
2 weeks to allow for complete clearance of drugs. A
standard breakfast or lunch was provided at the beginning
of each test day, to ensure equal states of metabolism on
both test days. Subjects were instructed not to use cannabis
from 2 weeks before the first test day until study
completion. Clearance of drugs was tested by means of a
urine sample at the beginning of each test day. Additionally,
no alcohol was permitted in the 48 h preceding a test day,
and subjects needed to refrain from smoking, eating, and
drinking during 4 h preceding each session.
Drug administration
On test days, subjects received THC or placebo by means
of a Volcano® vaporizer (Van Hell et al. 2011; Zuurman et
al. 2008) at four time points. The first dose consisted of
6 mg THC or placebo. To maintain average stable levels of
intoxicating effects throughout the experiment, upload
dosages of 1 mg were used, 30 min apart, as predicted
from previously described dose–effect relationships
(Strougo et al. 2008). After the first three administrations
of THC or placebo, subjects performed several cognitive
tasks during which fMRI scans were obtained. After the last
dose of THC or placebo, a battery of neuropsychological
tasks was performed (see also Van Hell et al. 2011). Here,
results are reported for the monetary incentive delay (MID)
task, results of other assessments are reported elsewhere.
Drug effects
Venous blood samples were collected to determine plasma
concentrations of THC and its two most important metabo-
lites,11-OH-THC and11-nor-9-carboxy-THC.Blood samples
were processed according to Zuurman et al. (2008).
Subjective effects were measured at baseline and before
and after each task and throughout the test day using self-
reported visual analogue scales (VAS) (Bond and Lader
1974; Bowdle et al. 1998). Heart rate and respiratory
function were monitored continuously during scanning.
Heart rate was assessed by measuring the electrocardiogram
using four electrodes attached to the subject's chest, and
respiratory function was assessed by measuring the expan-
sion of a respiration band around the subject's abdomen.
Task
The MID task was based on the paradigm described by
Knutson et al. (2001a) (see also Van Hell et al. (2010) and
Fig. 1). The task consisted of 48 trials, each lasting 8 s on
average (range 6–12 s). At the beginning of each trial, a cue
waspresentedsignalingatrialinwhicharewardcouldbewon
(“reward trial”, a circle) or a trial that was never rewarded
(“neutral trial”, a square).After the cue,a target waspresented
for a very short time, and subjects had to press a button before
the target disappeared. After each reward trial, feedback was
given which indicated a successful (“hit”)o ru n s u c c e s s f u l
response (“miss”) with the amount of money won (respec-
tively “2e u r o s ” or “0e u r o ”), as well as the total reward.
Anticipation time (the time between cue and target) and inter
trial interval were varied (4.3–10.3 s; mean 6.6 s, and 0–30 s;
mean 4.2 s, respectively).
Prior to the experiment, ten practice trials were presented
to familiarize subjects with the task. From the practice data,
the shortest reaction time to a target was used to determine
an individual threshold. Half of the targets in reward trials
were presented 200 ms longer than the individual threshold,
and half of the trials 150 ms shorter to ensure a close to
equal number of correct and incorrect responses, to achieve
optimal statistical power, as well as a similar total monetary
reward for all subjects. Neutral trials were presented with
an identical distribution as reward trials.
Scanning parameters
Image acquisition was performed on a Philips Achieva 3.0
Tesla MR scanner with a Quasar dual gradient set.
Fig. 1 MID paradigm (see also Van Hell et al. (2010))
Table 1 Demographic characteristics and patterns of drug use
Subject characteristics (n=11) Mean±SD Range
Age 21.7±2.3 18–27
IQ 104.5±6.0 94–111
Nicotine use last year (cigarettes/week) 3.0±8.4 0–28
Alcohol use last year (units/week) 16.7±8.7 2–40
Cannabis use last year (no. occasions) 17.9±13.4 5–52
Illicit use lifetime (no. occasions) 1.3±1.6 0–4
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PRESTO scan protocol (Neggers et al. 2008; scan param-
eters: TR 22.5 ms; TE 33.2 ms; flip angle=10°; FOV 224×
256×160; matrix 56×64×40; voxel size 4.0 mm isotropic;
scan time 0.6075 s; 40 slices; sagittal orientation, 1,182
volumes). A high-contrast volume with a flip angle of 27°
(FA27) was scanned for registration purposes. Before the
functional imaging run, a high-resolution whole brain
anatomical scan was performed (scan parameters: TR
9.4 ms; TE 4.7 ms; flip angle=8°; FOV 220.8×240×
159.6; matrix 368×400×113; voxel size 0.6×0.6×0.6 mm,
266 slices; sagittal orientation).
Analysis
Behavioral and physiological measures
VAS scores were corrected for baseline values and analyzed
using repeated-measures ANOVA with drug and time as
within-subject factors (Van Hell et al. 2011; Zuurman et al.
2008). Mean heart rate during the MID task was calculated
for placebo and THC sessions separately.
Task performance
Reward task performance was measured using reaction
times (RT) on neutral and rewarding trials. A repeated-
measures analysis with drug (two levels: THC and placebo)
and condition (two levels: reward and neutral) was
performed to analyze differences between THC and
placebo, and rewarding and neutral trials.
fMRI
Functional MRI data were preprocessed and analyzed using
SPM5 (Wellcome Trust Centre for Neuroimaging, London,
UK). Preprocessing of data consisted of realignment of
functional images and coregistration with the anatomical
volume using the FA27 volume. After realignment, func-
tional scans were spatially normalized into standard MNI
space and smoothed (FWHM=8 mm) to reduce the effect
of between-subject spatial variability in activation.
For each individual subject, regression-coefficients for
each voxel were obtained from a general linear model
regression analysis using a factor matrix that contained
factors representing event-related changes time-locked to
anticipation and feedback of neutral and reward trials (hits
and misses modelled separately). All factors were con-
volved with a canonical hemodynamic response function.
For anticipation, the variable anticipation period was used
as the expected duration of brain activity. For feedback, a
fixed period (duration of feedback period) was used as the
expected duration of brain activity. To reduce the presence
of slow trends in the signal, a high-pass filter with a cut-off
frequency of 0.007 Hz was applied to the data.
As this is the first study exploring the effects of THC
administration on reward processing in the brain, we
chose to perform region of interest (ROI) analyses on
areas that were involved in this particular task. This
approach has been described previously as a powerful
approach to explore data in a complex design (see
Poldrack (2007)). Group activation maps were created
for placebo and THC sessions separately. ROIs were
calculated based on two contrasts that were sensitive for
signal changes related to reward. The first group map
contrasted anticipation of rewarding targets versus antic-
ipation of neutral targets (denoted as “ANT”). The
second group map contrasted feedback of rewarded
targets versus feedback of missed targets (denoted as
“FB”). ROIs were constructed by clustering neighbouring
voxels that reached threshold in either the placebo or the
THC session (ANT thresholded at t>3.2, p<0.005; FB
thresholded at t>4.1, p<0.001). Constructing the ROIs
based on the highest values in either the THC or the
placebo session prevents bias towards our hypothesis
(Kriegeskorte et al. 2009; Vul et al. 2009). Mean signal
change for each ROI, each subject and each condition
were based on beta values averaged over voxels in each
ROI, extracted using Marsbar (Brett et al. 2002).
All hypothesis tests were performed using SPSS 15. To
measure THC effects on anticipation, an overall repeated-
measures MANOVA was performed on ANT ROIs with
drug (two levels: THC and placebo), condition (two levels:
reward and neutral), and ROI (fourteen levels) as within-
subjects factors. Follow-up ANOVA analyses were per-
formed for every ROI separately with drug and condition as
within-subjects factors.
To measure effects of THC on reward feedback activity,
repeated-measures MANOVAwere performed on FB ROIs,
for neutral and reward trials separately, with drug (two
levels), condition (two levels: hits and misses), and ROI
(ten levels) as within-subjects factors. Follow-up ANOVA
analyses were again performed for every ROI.
Results
Behavioral results
THC plasma concentration reached a maximum of 60.1±
33.7 ng/ml 5 min after inhalation of 6 mg THC and
decreased rapidly thereafter (also see Van Hell et al. (2011)).
Repeated-measures ANOVA with drug (two levels) as
within-subject factor showed that THC administration
increased subjective scores of “feeling high” (F(1,10)=
10.4, p<0.01) and heart rate (F(1,10)=8.0, p<0.02). THC
984 Psychopharmacology (2012) 219:981–990decreased “alertness” (F(1,10)=6.6, p<0.03) and induced
a trend towards increased “internal perception” (reflecting
inner feelings that do not correspond with reality)
(F(1,10)=3.6, p<0.09) (see Table 2).
Performance MID task
Repeated-measures ANOVA with drug (two levels) and
condition (two levels) as within-subject factors showed
a significant effect of condition (F(1,10)=22.0, p=
0.001), indicating that subjects were faster on reward
trials than on neutral trials, and a near significant effect of
drug (F(1,10)=4.5, p=0.06), indicating that subjects were
slower after THC administration compared to placebo (see
Fig. 2). A post hoc paired t test per condition indicated
that this effect was most pronounced during reward trials
(t=2.2, p=0.051).
fMRI results
Anticipation
ANT ROIs included left and right caudate nucleus, left and
right parietal cortex, middle cingulate, left and right
cerebellum, left pre/postcentral gyrus, left insula, anterior
cingulate/supplementary motor area, right inferior orbito-
frontal gyrus, right middle and inferior frontal gyrus, and
the thalamus/brain stem (see Fig. 3a and Figure S1 and
Table S1a).
Repeated-measures MANOVA revealed no significant
effect of drug (F=0.01, p=0.9) or drug by condition (F=
0.03, p=0.9) (see Fig. 4a). A significant drug by condition
by ROI interaction effect (F=2.5, p<0.05) indicated that
drug by condition effects differed between ROIs. Follow-up
analysis per ROI (not corrected for multiple comparisons)
revealed no significant drug effect in individual ROIs. One
ROI, the right inferior orbitofrontal gyrus, showed a
significant drug by condition interaction effect (F=7.9, p<
0.05; see Fig. 4b and Table S1b). This interaction was a
result of a larger signal increase in anticipation of a reward
after THC administration than after placebo administration.
However, the individual ROI effect did not survive
correction for multiple comparisons.
Feedback
FB ROIs included the inferior parietal and temporal gyrus
bilaterally, posterior and anterior cingulate, middle orbito-
frontal gyrus, and right superior frontal gyrus (see Fig. 3b
and Figure S2 and Table S2a). No differences were found in
FB ROIs between THC and placebo during neutral
feedback (see Fig. 5a). A repeated-measures MANOVA
showed that during reward trials, THC administration
caused a significant reduction in reward-related brain
activity (drug effect, F=13.1; p<0.01; see Fig. 5a), indi-
cating that THC reduced the signal for hits as well as
misses. Further analysis per ROI (not corrected for multiple
comparisons; see Fig. 5b and Table S2b) showed that this
main drug effect was present in the left inferior parietal
cortex (F=5.5, p<0.05), inferior temporal gyrus bilaterally
(left, F=8.2, p<0.05 and right, F=7.4, p<0.05), and at
trend level in the posterior cingulate (F=4.8, p<0.1) and
right inferior parietal cortex (F=4.2, p<0.1).
In addition, an overall interaction effect of drug by
condition by ROI (F=4.6; p=0.001) was found, indicating
that the drug by condition effect differed between ROIs.
This interaction was a result of the fact that two
d i f f e r e n td r u gb yc o n d i t i o ni n t e r a c t i o ne f f e c t sw e r e
found in individual ROIs: THC decreased the signal
Fig. 2 Performance of the MID task. Error bars denote Standard Error
of the Mean (SEM)
Table 2 Physiological and behavioral effects of placebo and THC
(mean±SD)
Placebo THC p
Heart rate (beats per minute) 68.9±8.5 83.8±20.8 0.018
a
VAS feeling high 0.2±0.8 19.5±19.9 0.009
a
VAS internal perception −0.4±1.5 1.3±2.7 0.086
VAS external perception 1.5±2.5 6.7±9.6 0.13
VAS alertness −1.5±7.8 −10.6±9.7 0.028
a
VAS contentedness −1.5±4.7 −4.2±4.8 0.11
VAS calmness 1.5±7.9 1.8±10.7 0.94
aSignificant difference between THC and placebo
Psychopharmacology (2012) 219:981–990 985change for a miss but not for a hit in the posterior
cingulate (F=6.3, p<0.05) and the middle orbitofrontal
cortex (F=12.6, p<0.01), while THC reduced the signal
change related to a hit but not a miss in the right superior
frontal cortex (F=6.7, p<0.05). A trend for an interaction
effect of drug by condition in the left inferior temporal
gyrus indicated a larger attenuation of brain activity during
hits than misses after THC administration (F=3.5; p<0.1).
However, none of these ROI effects survived correction
for multiple comparisons (see Tables 3, 4,S 1ba n dS 2b).
Discussion
In this study, the role of the eCB system in reward
processing in humans was examined by assessing the
effects of THC administration on brain activity during
monetary reward anticipation and feedback. Subjects
showed similar behavioral responses to reward during
THC and placebo, with faster responses if a reward could
be won. THC administration attenuated brain activity
during reward feedback compared to placebo. THC did
not affect brain activity related to feedback if there was no
possibility to win a reward. These results indicate that THC
administration predominantly reduces the effect of feedback
in situations where there is the possibility to earn a reward
and suggest involvement of the eCB system in appreciation
of a received reward. This effect was largest in the inferior
Fig. 4 Brain activity during anticipation. a Brain activity during
anticipation averaged across ROIs; b right inferior orbitofrontal
cortex. Error bars denote standard error of the mean (SEM). a.u.=
arbitrary units; R=right; Inf=inferior. p values are not corrected for
multiple comparisons
Fig. 3 Regions of interest;
based on pooled group activation
maps of THC and placebo; a
reward anticipation; b reward
feedback. L=left, R=right
986 Psychopharmacology (2012) 219:981–990parietal and temporal cortex. The inferior parietal cortex is
a pivotal part of the attention network (Naghavi and Nyberg
2005; Pessoa et al. 2002). More specifically, the inferior
parietal cortex is associated with a salience representation
of the outside world (Gottlieb 2007), indicating that
attention is directed towards salient- or task-relevant
objects. Previous studies have shown that eCB affects
inferior parietal cortex function, as decreased activity has
been reported after THC administration in association with
auditory attention (Roser et al. 2008) and during emotional
processing (Fusar-Poli et al. 2009). Hence, our result
suggests a general effect of THC on attentional processes
during salient feedback.
Subjects reacted faster on the task when a reward could
be won, during both THC and placebo, an effect that has
been reported previously (Knutson et al. 2001b; Bjork and
Hommer 2007). This indicates that subjects were motivated
to perform the task during both placebo and THC. However,
Fig. 5 Brain activity during feedback. a Brain activity during
feedback averaged across ROIs; b reward feedback in separate ROIs.
Error bars denote standard error of the mean (SEM). L=left, R=right;
Inf=inferior; Sup=superior; Post=posterior; Cx=cortex; a.u.=arbi-
trary units. Single asterisk significant drug effect (p<0.05); double
asterisk significant drug by condition interaction effect (p<0.05). p
values are not corrected for multiple comparisons
Area Max T Cluster size MNI coordinates
xyz
1 L cerebellum 4.6 42 −32 −52 −32
2 R cerebellum 4.2 31 44 −48 −24
3 Brain stem 4.5 68 0 −20 −12
4 R inferior orbitofrontal cortex 8.7 27 28 24 −24
5 L insula 6.5 49 −44 12 8
6 L caudate 4.2 30 −844
7 R caudate 6.0 70 12 8 0
8 L pre/postcentral gyrus 4.4 209 −48 −24 56
9 SMA/anterior cingulate 5.8 326 0 −46 0
10 Posterior cingulate 4.8 36 −12 −72 44
11 L superior parietal cortex 5.5 65 −40 −60 60
12 R precentral gyrus 7.1 123 48 0 40
13 R middle frontal cortex 7.9 37 40 44 32
14 R superior parietal cortex 4.9 71 12 −72 44
Table 3 Regions of interest
during reward anticipation
Max T maximum T value, R
right, L left
Psychopharmacology (2012) 219:981–990 987subjects were slower after THC administration during both
neutral and reward trials, indicating that THC has a more
generalized motor or attentional effect in addition to the
reward-specific effects observed in the present study. Indeed,
another study assessing the effects of acute THC administra-
tion reported that THC can increase reaction times on a
number of tasks assessing either memory, attention, or simple
reaction times (Curran et al. 2002).
Analyses of individual ROIs yielded some effects of
THC (described in the “Results” section), but none
survived the corrected threshold for multiple comparisons.
They do suggest that brain activity during feedback was
attenuated most in the posterior cingulate, the superior
frontal cortex, and orbitofrontal cortex. These have all been
associated with reward processing (Hayden et al. 2008;
McCoy and Platt 2005; Tabuchi et al. 2005; Dom et al.
2005; Egerton et al. 2005; Wallis and Kennerley 2010)o r
effects of THC administration (Fusar-Poli et al. 2009;
Stokes et al. 2010). Nevertheless, the most robust finding
was a network-wide effect of THC.
The eCB system has been implicated in various aspects
of addiction, such as drug-seeking and relapse (De Vries
and Schoffelmeer 2005). Animal studies showed that
activating the eCB system with an agonist provoked relapse
to use of other drugs, suggesting a generic but complex role
for eCB in reward (Wiskerke et al. 2008). Blocking the eCB
system with the antagonist rimonabant led to the opposite
effect, reducing drug-seeking and relapse (De Vries et al.
2001). One could argue that if THC activates the eCB
system and thereby induces mild elevation of activity of the
reward system (Bossong et al. 2009; Stokes et al. 2010), the
impact of other rewarding stimuli may be dampened as a
result, thus explaining the attenuation of brain activity due
to a monetary reward. An indication for such a mechanism
can be derived from the effect of chronic cannabis use on
motivation in general. Although there is no clear evidence
for loss of motivation, the negative effects of chronic
cannabis use on school performance and later life outcomes
may be seen as an indication (Fergusson and Boden 2008),
but this interpretation warrants further investigation.
In our study, anticipation of a reward activated the
striatum, insula, anterior cingulate, and frontal brain
regions, and feedback of reward activated the posterior
and anterior cingulate, inferior parietal cortex, orbitofrontal,
and superior frontal cortex. This pattern of brain activity is
in line with previous reward imaging studies, which have
reported striatal activity during anticipation and frontal
activity during feedback of reward (Bjork and Hommer
2007; Knutson et al. 2001a; Knutson and Cooper 2005;
O'Doherty 2004).
The nucleus accumbens did not show significantly
elevated activity during reward anticipation in our study.
Additional ROI analyses with the nucleus accumbens as an
anatomically defined ROI also did not show a significant
effect of THC (data not shown). Factors that may have
reduced effects of reward in the striatum and nucleus
accumbens include the fact that subjects were paid
250 euros for participation in the study. An extra reward
of 24 euros that was won during the reward task may have
been too small in comparison. Specifically for the nucleus
accumbens, it can be noted that fMRI measurements in this
region tend to be less reliable, as it is located close to the
nasal cavity, which reduces the BOLD signal to noise ratio.
The significant anticipatory effect of reward in striatum
was slightly reduced after THC, but this effect was too
small to become significant. This is contrary to what we
expected, as the striatum shows high densities of CB1
receptors, and THC is known to elicit rewarding and
dopamine-elevating effects on the striatum (Bossong et al.
2009; Gardner 2005). However, recent studies in humans
indicated that the role of THC in increasing dopamine
levels in the striatum may be limited (Stokes et al. 2009;
Barkus et al. 2011). Effects of THC in the striatum may also
have been influenced by the fact that our subjects were
Area Max T Cluster size MNI coordinates
xyz
1 L inferior temporal cortex 8.5 43 −56 −64 −20
2 R inferior temporal cortex 8.3 51 60 −60 −20
3 Middle orbitofrontal cortex 6.1 31 −46 0−4
4 Medial superior frontal cortex 8.7 30 16 68 16
5 L inferior parietal cortex 15.4 350 −32 −68 36
6 Posterior cingulate 6.4 202 −4 −48 28
7 Anterior cingulate 6.1 30 0 8 32
8 R angular gyrus 8.3 132 40 −68 40
9 R inferior parietal cortex 8.7 39 56 −40 48
10 R superior frontal cortex 5.9 27 16 20 52
Table 4 Regions of interest
during reward feedback
Max T maximum T value, R
right, L left
988 Psychopharmacology (2012) 219:981–990occasional users of cannabis (see also Van Hell et al. 2010).
It may also be possible that the effect of THC on striatal
activity is domain specific, and limited for anticipatory
reward activity. There have not been any previous studies
examining effects of THC on striatal reward processing
activity to compare our results to, but previous studies
using different cognitive paradigms have shown attenuation
of ventrostriatal activity after THC during retrieval of
memory (Bhattacharyya et al. 2009) and an increase in
brain activity in the caudate during response inhibition
(Borgwardt et al. 2008), which would be in line with the
hypothesis that THC effects may be domain specific.
The results from the current study should be interpreted
with due care. Our sample size was small for an fMRI study
whichcomparesdatabetween sessions.A larger samplecould
have revealed more effects of THC, for instance, during task
anticipation in striatal areas. In addition, although the study
was designed to be double blind, THC induced behavioral
effects that were identified by most subjects, possibly causing
expectancy effects across sessions. The influence of expec-
tancy was minimized by using a randomized cross-over
design, thus balancing expectancy effects across sessions.
Still, it cannot be excluded that expectancy effects may have
affected our results to some extent.
In conclusion, this study provides new arguments for eCB
involvement in the reward system in humans. Findings
suggest thatTHCaffects appreciationofobtaininga monetary
reward. The involvement of the eCB system in feedback
processing may be relevant for disorders in which apprecia-
tion of natural rewards may be affected such as addiction.
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